Knowledge Library

Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte models of hepatitis B

WuXi AppTec scientists recently contributed to a research study published in the journal Hepatology, characterizing the efficacy of prodrug DF-006 for treating chronic hepatitis B infection. DF-006 is an orally active agonist of alpha‐kinase 1, a pattern recognition receptor involved in the stimulation of innate immunity.  The authors show that DF‐006 is efficacious in hepatitis …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Immunology Infectious Diseases Liver Diseases Small Molecules

VIEW

OncoWuXi Newsletter December 2022

Resource Type: Latest Science Newsletter
Resource Topic: Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Candidate Selection Cell-based Assays CRISPR/Cas9 DRUG DISCOVERY AND INNOVATION Hit Finding Hit-to-Lead Immunology Lead Optimization Oncology Phenotypic Assays Rare Diseases Target Identification and Validation Tumor Models

VIEW

Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses

While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >

Resource Type: Latest Science Poster
Resource Topic: Biomarkers Cell-based Assays Immunology in vitro biology Oncology Oncolytic Viruses Phenotypic Assays Target Identification and Validation

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics CRISPR/Cas9 Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Manipulation Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery

We have established an advanced and integrated in vitro and in vivo platform for various types of cancer vaccines, including peptide vaccines, mRNA vaccines, DC vaccines and more. Ovalbumin (OVA) is a key model antigen which has been widely used in vaccination experiments. Here we established an OVA overexpressed system based on different types of …Read More >

Resource Type: Latest Science Poster
Resource Topic: Biomarkers Cell-based Assays Immunology in vitro biology Lead Optimization Oncology Target Identification and Validation Target-Specific Assays Tumor Models

VIEW

Establishment of spatial transcriptomics assay to find the mechanism of immune therapy against tumors

Intra-tumor heterogeneity is one of the biggest challenges in cancer treatment today, not only on cell types and functions, but also on the spatial pattern of immune cells within the tumor tissue. While most of  single-cell RNA sequencing technologies enable the exploration of gene expression heterogeneity at the single cell level, they cannot provide spatial …Read More >

Resource Type: Latest Science Poster
Resource Topic: Biomarkers Immunology Oncology Target Identification and Validation Tumor Models

VIEW

Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response

Ionizing radiation has largely been recognized as a local targeted therapy by a variety of mechanisms, including inducing direct DNA damage of cancerous tissue or contributing to systemic antitumor immunity. The capacity of cancer cells to recognize DNA damages and initiate repair plays a major role in radio-resistance. Furthermore, the irradiated tumor cell death can …Read More >

Resource Type: Latest Science Poster
Resource Topic: Cell-based Assays Immunology in vitro biology Oncology Tumor Models

VIEW

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion

Cancer cells acquire genetic heterogeneity to escape from immune surveillance during tumor evolution, but a systematic approach to distinguish driver from passenger mutations is lacking. Here we investigate the impact of different immune pressure on tumor clonal dynamics and immune evasion mechanism, by combining massive parallel sequencing of immune edited tumors and CRISPR library screens …Read More >

Resource Type: Latest Science Publication
Resource Topic: Antibodies CRISPR/Cas9 Immunology Oncology Screening Libraries Target Identification and Validation Target-Specific Assays Tumor Models

VIEW

Evaluation of the efficacy of ADC in vitro and in vivo

Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, an ADC-derived monoclonal antibody is conjugated with cytotoxic agents (payloads) which can deliver potent cellular toxins to targeted cancer cells specifically. We have established a state-of-the-art platform …Read More >

Resource Type: Poster
Resource Topic: Antibody Drug Conjugate Biochemical Assays Biomarkers Cell-based Assays Immunology in vitro biology Lead Optimization Oncology Tumor Models

VIEW


Resource Topics